Clinical risk factors in SUDEP
A nationwide population-based case-control study
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received May 4, 2019
- Accepted in final form August 5, 2019
- First Published December 12, 2019.
Article Versions
- Previous version (December 12, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Olafur Sveinsson, MD, MSc,
- Tomas Andersson, BSc,
- Peter Mattsson, MD, PhD,
- Sofia Carlsson, PhD and
- Torbjörn Tomson, MD, PhD
- Olafur Sveinsson, MD, MSc,
1) Advisory board for Biogen Idec on the medication Plegridy for MS.
NONE
1) Travel funding from Biogen Idec 2) Travel funding from UCB 3) Travel funding from Sandoz
NONE
NONE
NONE
NONE
1) Consultant for Biogen Idec on Plegridy and Zinbryta.
NONE
Received consulting fees from Biogen, other from Biogen, other from UCB and Sandoz, outside the submitted work.
NONE
NONE
1) The study was supported by Stockholm County Council, GlaxoSmithKline and Citizens United for Research in Epilepsy (CURE).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tomas Andersson, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Peter Mattsson, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Meducan Limited
NONE
NONE
NONE
NONE
NONE
Uppsala County Council
Epilepsifonden Selander Foundation CURE (with prof Tomson) Stock/Stock Options, Medical Equipment & Materials: Elekta AB
NONE
NONE
NONE
NONE
NONE
NONE
- Sofia Carlsson, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Grants from the Swedish Research Council, Swedish Diabetes Association, Swedish Research Council for social and working life (other research)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Torbjörn Tomson, MD, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (O.S. T.T.), Karolinska University Hospital; Department of Clinical Neuroscience (O.S. T.T.) and Institute of Environmental Medicine (T.A., S.C.), Karolinska Institutet; Center for Occupational and Environmental Medicine (T.A.), Stockholm County Council; and Department of Neuroscience (P.M.), University of Uppsala, Sweden.
- Correspondence
Dr. Sveinsson olafur.sveinsson{at}sll.se
Article usage
Letters: Rapid online correspondence
- Author response: Clinical risk factors in SUDEP: A nationwide population-based case-control study
- Olafur Sveinsson, Neurologist, Karolinska Institutet
Submitted December 28, 2019 - Reader response: Clinical risk factors in SUDEP: A nationwide population-based case-control study
- Nitin K. Sethi, Associate Professor of Neurology, New York-Presbyterian Hospital, Weill Cornell Medical Center (New York, NY)
Submitted December 16, 2019
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Pharmacologic treatment and SUDEP riskA nationwide, population-based, case-control studyOlafur Sveinsson, Tomas Andersson, Peter Mattsson et al.Neurology, September 23, 2020 -
Article
SUDEP in the North American SUDEP RegistryThe full spectrum of epilepsiesChloe Verducci, Fizza Hussain, Elizabeth Donner et al.Neurology, June 19, 2019 -
Article
Proteomics and Transcriptomics of the Hippocampus and Cortex in SUDEP and High-Risk SUDEP PatientsDominique F. Leitner, James D. Mills, Geoffrey Pires et al.Neurology, April 28, 2021 -
Special Article
Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factorsReport of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy SocietyCynthia Harden, Torbjörn Tomson, David Gloss et al.Neurology, April 24, 2017